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Abstract
Immature dendritic cells (DC) represent potential clinical tools for tolerogenic cellular immunotherapy in both
transplantation and autoimmunity. A major drawback in vivo is their potential to mature during infections or inflammation,
which would convert their tolerogenicity into immunogenicity. The generation of immature DC from human bone marrow
(BM) by low doses of GM-CSF (lowGM) in the absence of IL-4 under GMP conditions create DC resistant to maturation,
detected by surface marker expression and primary stimulation by allogeneic T cells. This resistence could not be observed
for BM-derived DC generated with high doses of GM-CSF plus IL-4 (highGM/4), although both DC types induced primary
allogeneic T cell anergy in vitro. The estabishment of the anergic state requires two subsequent stimulations by immature
DC. Anergy induction was more profound with lowGM-DC due to their maturation resistance. Together, we show the
generation of immature, maturation-resistant lowGM-DC for potential clinical use in transplant rejection and propose a two-
step-model of T cell anergy induction by immature DC.
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Introduction
Establishment of immunological tolerance is the ultimate goal
for causative treatments of autoimmune diseases, allergies and
transplant rejections. While T cells are major effectors in
autoimmune responses, DC are not only potent inducers T cell
immunity but also control T cell tolerance [1,2]. There is
considerable interest in the generation tolerogenic DC to control
autoreactive T cells in human patients [3]. With the diversity of T
cell tolerance mechanisms, there might not be a single tolerogenic
DC type able to control all of these mechanisms. Therefore it is
important to select or generate the optimal tolerogenic DC type
that is best suited to tolerize a specific disease.
The various mechanisms of T cell tolerance can be subdivided
into T cell-intrinsic mechanisms, such as T cell anergy, deletion,
immune deviation and T cell extrinsic control by induction of
regulatory T cells (T regs) [4,5,6,7]. T cell anergy induction has
been originally described with T cell clones, i.e. cells that have
undergone at least one stimulation before employed in the anergy
experiments [8]. Subsequent exposure of such primed, but resting
CD4+ T cells cross-linked to CD3 resulted in an anergic state of
these cells. Characterized by their inability to respond to
subsequent TCR signals, but ability to maintain proliferative
capacity by polyclonal stimulation. Previous studies indicate T cell
anergy could be induced by a single application of orally applied
ovalbumin antigen [9] or superantigen [10].
Although detailed molecular mechanisms of signal transduction
to induce T cell anergy have been identified [4], the physiological
type of antigen-presenting cell (APC) inducing anergy has not been
investigated. Although it has been postulated that a single hit may
not be sufficient to induce T cell anergy the need for a single or
sequential trigger of naı¨ve T cells by anergy-inducing APC
remains largely unclear [11].
The ability of T cell anergy induction could be achieved with
CD3 antibodies in the absence of CD28 costimulation. A cellular
counterpart that provides TCR/CD3 signals without CD28
engagement is represented by immature DC, characterized by a
low expression of surface MHC II molecules and low to absent
levels of costimulation by CD80/CD86. Technically, the preser-
vation of an immature state remains difficult for in vitro generated
DC since murine or human immature DC spontaneously mature
[12]. These cells are highly sensitive to culture conditions [13], or
inflammatory, microbial and T cell-derived stimuli [14,15]. For in
vivo application of immature tolerogenic DC it is mandatory to
block their maturation [16]. A specific maturation block to
preserve the immature DC phenotype was first described by
treatment of human Langerhans cells with UV light [17].
Thereafter, many other treatments have been reported to inhibit
DC maturation, including IL-10, TGF-b, glucocorticoids and
vitamin D3 analogues [reviewed in [7]. However, only few reports
exist, where immature DC could be generated in vitro that were
resistant to further maturation signals. These methods include the
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combined treatment of DC with IL-10 plus TGF-b [18],
dexamethasone or rapamycin [19] or vitamin D3 analogues
[20]. DC blocked with combined IL-10 plus vitamin D3 treatment
have already been applied sucessfully in macaques [21].
Immature DC have been also applied in vivo to delay allogeneic
transplantations in mice. Despite the positive effect on the graft
survival, the delay of rejection was only moderate as DC
maturation occurred in vivo, shown by B7-2 upregulation [22].
This further underlined the prerequisite of maturation-resistance.
In the same allogeneic heart transplantation model, pretreatment
of mice with immature and maturation-resistant DC allowed a
prolonged graft survival as compared to normal immature DC
[22]. These immature and maturation-resistant DC were gener-
ated from murine BM cells by using very low doses of GM-CSF
(5–20 U/ml) in the absence of IL-4 [23].
Here we show that human bone marrow cells, when cultured
with low doses of GM-CSF, give rise to immature DC that do not
respond to maturation stimuli anymore, similarly demonstrated in
the mouse model. These human immature and maturation-
resistant DC should be safer as compared to normal immature DC
for tolerance induction in clinical applications of transplant
rejection or T cell-mediated autoimmune diseases.
Results
Human BM-DC generated under lowGM conditions are
maturation resistant
The standard source for the generation of human DC are
peripheral blood monocytes, while in the murine system, DC are
mostly generated from BM. Previously, we described a method
how murine DC can be generated with low doses of GM-CSF
from BM cells without undergoing spontaneous maturation. These
lowGM-DC remained at their immature state and were resistant
to stimulation with TNF, LPS or CD40 ligation [23]. As
maturation-resistance is advantageous for the clinical application
of tolerogenic DC, we investigated whether such DC could be
generated from human BM.
Human BM cells were cultured following the murine protocol to
generate lowGM-DC. After 6 days, the cells were analyzed for
their expression of typical markers for mature DC. LowGM-DC
and control DC generated with high doses of GM-CSF plus IL-4
(highGM/4), similar to protocols for human monocyte-derived
DC, yielded the same cell numbers after 6 days (Fig. 1A).
However, the cellular yields from highGM/4 cultures were slightly
higher as compared to lowGM conditions. These cells also
expressed low levels of HLA-DR being consistent with an
immature DC phenotype (Fig. 1B and C). Together, under either
of the two conditions 56106 BM cells yielded 2.5–4.46105 DC,
respectively. Upon stimulation with LPS only the highGM/4
upregulated CD40, CD83, CD86 and HLA-DR, while the
lowGM cells retained their immature DC profile (Fig. 1C). Similar
results were obtained by stimulation with a standard maturation
cocktail (TNF, IL-1b, IL-6, PGE2), CD40 ligation or with the
TLR3 ligand Poly I:C (not shown).
Matured lowGM-DC remain functionally immature in
stimulating an allogeneic MLR
To further substantiate the phenotypical results, we compared
lowGM-DC with highGM/4-DC in their capacity to prime naı¨ve
allogeneic T cells. Both types of DC were used as immature cells or
after treatment with various maturation stimuli. While immature
and mature lowGM-DC showed weak T cell stimulation capacity
with the maximal response being less 35,000 cpm (Fig. 2A). In
contrast, highGM/4-DC showed a maximal T cell stimulation
capacity of 40,000 cpm already by immature DC and could be
further upregulated after maturation (Fig. 2B).
A single stimulation by immature DC does not induce T
cell anergy
In our murine experiments, we observed the induction of T cell
anergy by a single injection of lowGM-DC into allogeneic mice
([23] and unpublished observations). To tested whether lowGM-
DC would be able to induce allogeneic T cell anergy in vitro,
immature lowGM-DC and highGM/4-DC were generated from
BM and compared to LPS-matured DC generated from PBMC.
All these three DC types were co-cultured with allogeneic T cells
for 5 days. Then the T cells were restimulated with different
stimuli, such as high doses of IL-2 or anti-CD3, either alone or in
combination with anti-CD28. These conditions were also repeated
with mature monocyte-derived DC (Mo-DC) from the same donor
as in the first stimulation, or mature Mo-DC from a third party
donor. Under all conditions a mild proliferation of T cells could be
observed, which was at the same level or slightly higher than the
unstimulated T cells (Fig. 3). Thus, T cell anergy was not induced
under all of these conditions. Shortening (3 days) or extending (7,
10 days) the time interval before restimulation did not modify this
result (not shown).
Two stimulations by lowGM-DC are required to induce T
cell anergy
T cell anergy induction has been proposed by some authors to
require a single TCR stimulation in vitro or a single injection of an
antigen. However, data by other groups indicated that prestimula-
tion of the T cells would be required to establish T cell anergy
[11]. Many T cell anergy experiments described in the literature
were performed with antigen-experienced T cell clones. For T cell
anergy induction in vivo, soluble antigens were injected intrave-
nously. All of these in vitro studies employed antibodies for T cell
treatment and did not investigate the APC type in vivo. The precise
type of prestimulation was never assessed. The injected antigens
may be endocytosed by immature splenic DC, which present the
peptides to T cells and establish their anergic state after about 3
days. It is not clear whether a single T-DC contact is required to
result in T cells anergy or several rounds of contacts are needed
within this time period. In fact, a single encounter of naı¨ve T cells
with immature DC was not sufficient to render them anergic
(Fig. 3). To test whether T cell anergy induction in naı¨ve T cells
may depend on two stimulations, we cultured the allogeneic T cells
twice with the same type of DC. Now T cell anergy induction
could be clearly observed with both types of immature lowGM-
DC and highGM/4-DC, as indicated by their inability to respond
to a TCR signal alone (anti-CD3), by their lowered capacity to
respond to full T cell stimulation (allogeneic mature DC and the
anti-CD3/antiCD28 combination). Nevertheless their potential to
proliferate on polyclonal stimulation by IL-2 or to third party-
derived mature Mo-DC was not affected (Fig. 4B). Two repetitive
stimulations of the T cells with mature DC resulted in the expected
memory T cell phenotype with reduced costimulation require-
ment, as reflected by the capacity to respond to anti-CD3 alone
(Fig. 4B). In addition, T cells stimulated with mature DC and
followed by CD3 antibodies only showed a cytokine profile of
differentiated cells, such as high IFN-c, some IL-10 (Fig. 4C), but
almost no IL-2. IL-4 was never detected under all conditions (not
shown). Importantly, T cells in culture with lowGM-DC and
restimulated with anti-CD3 did not produce IL-2 or IL-10 in
relevant amounts, only little IFN-c (Fig. 4C). Also, it did not show
higher Foxp3+ cell frequencies in proliferated cells (allo-specific) as
Maturation-Resistant DC
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compared to non-prolifereted cells (not allo-responsive). This was
further comparable in cultures stimultated by highGM/4 or
mature DC (Fig. 4D). Thus, our data may indicate non-allo-
specific Foxp3+ regulatory T cells or IL-10 producing T regulatory
type-1 cells [24,25] were induced after two rounds of stimulation
with immature lowGM-DC or highGM/4-DC, but argue for the
induction of allogeneic T cell anergy.
The two stimulations by immature DC cannot be
substituted by mature DC at any time of stimulation
Anergy induction in naı¨ve T cells required two stimulations with
immature DC, while previous studies required only one stimula-
tion. However they used T cell clones or preactivated T cells. The
differential types of prestimulation by antibodies often employed
CD3 stimulation without CD28 costimulation. On the other hand
the state of activation or preactivation of T cell clones for anergy
induction was unclear. Therefore we wondered whether one of the
two stimulation could be substituted by mature DC. We
exchanged the immature lowGM-DC by mature highGM/4-DC
during the first or second round of stimulation. The results
indicate that only two subsequent stimulations by immature
lowGM-DC induced an absolute unresponsiveness to anti-CD3
and a relative unresponsiveness to anti-CD3/anti-CD28 with no
impairment to respond to IL-2 (Fig. 5). These data indicate that
both rounds of stimulation require immature DC and cannot be
substituted by mature DC at any time point.
Discussion
Here we described a method to generate human immature and
maturation-resistant DC from BM precursor cells which was
adopted from a murine protocol [23]. All reagents and media that
were used in this protocol were approved for GMP guidelines and
thus suitable for human clinical use. LowGM-DC were resistant to
common maturation stimuli and induced T cell anergy in naı¨ve
allogeneic T cells when stimulated twice with immature DC.
HighGM/4-DC were not maturation-resistant and induced T cell
anergy, but less profound compared to lowGM-DC. Untreated
Figure 1. Human BM-derived lowGM-DC do not upregulate surface markers upon maturation. Human BM cells were cultured under
standard conditions with 800 U/ml GM-CSF plus 250 U/ml IL-4 or under lowGM conditions with 5 U/ml GM-CSF for 6 days in RPMI+1% AB plasma. A.
The cells were harvested and counted under trypan blue exclusion. The mean values6standard deviations of 8 independent experiments are shown.
B. The harvested cells were analysed by flow cytometry by setting gates on large cells in the FSC/SSC profile and HLA-DR+ cells. C. Analysis of 3
independent experiments as gated in B. Mean values6standard deviations are shown. D. The cells were then exposed to 100 mg/ml LPS for 24 h to
induce maturation or left untreated and surface stained for the indicated markers (straight lines) or isotype controls (dotted lines). Cells were gated as
in B to exclude lymphocytes and precursor cells. The data from one experiment shown are representative of 5 independent experiments.
doi:10.1371/journal.pone.0006645.g001
Maturation-Resistant DC
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immature DC are extremely sensitive to all kinds of maturation
stimuli, even strong pipetting [26]. The achievement of matura-
tion-resistance is one prerequisite for the clinical application of
tolerogenic DC. Plans to introduce tolerogenic DC in human
clinical studies involve such maturation-resistant DC [19].
The phenomenon of maturation-resistance have been observed
also after treatment of DC with TGF-b plus IL-10 [27],
dexamethasone [28,29] or vitamin D3 analogues [20]. These
factors were found to induce a similar maturation-resistant
phenotype of DC. The resulting immature DC did either not
respond to conventional maturation stimuli or underwent an
alternative activation, that results in the production of tolerogenic
cytokines (IL-10, TGF-b) or the expression of tolerogenic surface
markers (ILT-3) (reviewed in [7]). The maturation stimuli tested on
these DC maturation-resistance included TLR ligands and
endogenous factors, such as proinflamatory cytokines (TNF) or
CD40 ligands, which reflect very different pathways of DC
activation. However, the underlying molecular mechanisms of
DCmaturation-resistance are not fully understood. DC treated with
vitamin D3 analogues showed an impaired NF-kB activation
leading to IL-12p40 gene repression [30]. When dexamethasone
treated DC were stimulated by LPS they showed a reduced IL-12
production but the IL-10 production was not affected [31],
indicating that an immunogenic DC maturation is blocked but an
suppressive activation pathway remains functional. The effect of
vitamin D3 analogues on DC function seems to result in a modified
DC phenotype expressing ILT-3, IL-10, and inducing T regs rather
than inducing T cell anergy [20]. Whether ILT-3 expression on DC
could represent a molecule to distinguish between the induction of
CD4+ T cell anergy or CD4+ T regs remains to be determined.
Analyses with CD4+ and CD8+ T cells strongly argue for a role of
ILT-3 on DC in the generation of suppressive T cells [32].
Figure 2. LowGM-DC remain functionally immature after maturation. DC were generated under low-GM (A) and standard highGM plus IL-4
conditions (B) for 6 days, stimulated with the indicated reagents or a ‘‘cocktail’’ consisting of TNF, IL-1b, IL-6 and PGE2 for 24 h and then added at
titrated numbers to allogeneic T cells, as represented by non-adherent fraction of PBMC of an allogeneic donor. After 3 days [3H]-thymidine was
added overnight to measure proliferation. The data from one experiment shown are representative of 3 independent experiments. Values represent
the mean6standard deviation error bars of triplicate cultures from one experiment.
doi:10.1371/journal.pone.0006645.g002
Maturation-Resistant DC
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We achieved a similar phenotype of maturation-resistant DC
when cord blood CD34+ cells were cultured under lowGM
conditions, however at lower cell yields (not shown). In contrast,
we were unable to apply the lowGM protocol to adherent
peripheral blood monocytes as a source of DC precursors (not
shown). This may indicate that earlier developmental stages and
precursors different from monocytes are required to induce this
type of differentiation.
In the murine system, the presence of IL-4 during the
generation of lowGM-DC abrogated the maturation-resistant
phenotype [23] and during normal highGM cultures can influence
the subset generation [33]. When IL-4 and IL-13 were added to
LPS during murine or human DC maturation they increased the
production of the Th1-inducing cytokine IL-12p70 [34,35].
Interestingly, IL-4 in equine DC generated from peripheral blood
has been shown to mature DC by its own [36]. All of these data
indicate IL-4 produced early during an infection by innate
immune cells may prime immature DC to switch to immunity or
enhance maturation induced by weak stimuli. When IL-4 was
added to the human lowGM-DC cultures we obtained mixed
results. For some donors IL-4 did not influence the maturation-
resistant phenotype, while other cultures lost their maturation-
resistance (not shown). Thus, it remains to be determined how the
influence of IL-4 (and IL-13) can be counteracted before the
clinical use of our lowGM-DC.
Previous reports indicated that repetitive in vitro stimulations of
human allogeneic T cells with immature Mo-DC resulted in the
generation of T regs [37]. Here we report that immature DC
generated from BM induced T cell anergy but not T regs. The
discrepancy may be explained by different cellular sources of the
DC precursors leading to different immature DC phenotypes. In
fact, immature Mo-DC express higher levels of HLA-DR and
costimulatory molecules, CD80 and CD86, (despite CD83 being
negative) as compared to human tissue-resident DC analyzed ex vivo
from liver [38], epidermis [38], or spleen [39,40]. In this respect
those tissue-derived DC resemble our immature DC generated from
BM (both lowGM and highGM/4). T cell anergy induction has
been previously shown by several groups to be mediated by
immature DC, while T regs require CD28 costimulation to be fully
functional. Thus, the CD80/CD86low immature BM-DC may
induce anergy, while the CD80/CD86int immature Mo-DC may
induce T regs. On the other hand, the induction of T regs is known
to depend on the presence or DC production of TGF- b, retinoic
acid, or IL-10. In addition immature splenic DC to induce T regs
[41]. In this view there may also exist differences between DC
derived from different precursors.
Anergy induction in naı¨ve allogeneic T cells by both lowGM-
DC and highGM/4-DC required two rounds of stimulation by
immature DC. It has been shown effector T cells and T cell clones
can be rendered anergic by a single TCR signal in the absence of
costimulation, but that in vivo suboptimal costimulation via CD80/
CD86 may be required to anergize naı¨ve T cells through CTLA-4
[11]. On the other hand in vivo examples indicate anergy induction
may be induced in the presence of co-stimulation independently of
CTLA-4 by blocking the cell cycle [42,43]. Also inversely, we
could show that in the absence of the two major cell cycle
inhibitors, p27Kip1 and p21Cip1, T cell anergy could still be
induced in mice [44]. Delineated from these data two distinct
pathways of T cell anergy induction have been proposed: one via
cell cycle inhibition and the other via CTLA-4 [45].
Recent data indicate that CTLA-4 upregulation is mediated via
the TCR as shown using CD3 antibodies [46]. Thus, the CD80/
CD86 expression by immature or mature DC may not contribute
to CTLA-4 upregulation. In a second stimulation immature DC
expressing low levels of CD80/CD86 may trigger preferentially
CTLA-4 on primed T cells, not CD28, due to a higher affinity of
CTLA-4 to its ligands and limited availablity of CD80/CD86
molecules at the surface of immature DC. Although further
analysis will be required to show a causal relationship between the
CTLA-4 upregulation and the requirement for a second hit by
immature DC, our data support a model depicting how T cell
anergy can be induced by two stimulations with immature DC,
providing a basis for the potential physiological mechanism of T
cell anergy induction via CTLA-4 also in vivo.
Our data indicate that a second stimulation with mature DC
after a first stimulation with immature DC will not lead to T cell
anergy. A higher level of CD80/CD86 expression on the surface
of mature DC as compared to immature DC, may trigger CD28,
as well as, trigger CTLA-4. When both ligands are encountered by
T cells, anergy induction may then be prevented by the dominant
CD28 signal. Indeed, early in vitro experiments investigating the T
cell priming by CD3/CD28/CTLA-4 antibody combinations
indicated CD28 can outcompete negative CTLA-4 signals
depending on their ratio [47]. Alternatively other costimulatory
molecules or cytokines expressed by mature DC could interfere
with the negative CTLA-4 signal [48] or via control of the spatial
and temporal expression kinetics of CD28/CTLA-4 on T cells and
CD80/CD86 on DC [49].
In the reverse setting, when mature DC were applied as the first
round of stimulation, complete T cell activation may have been
initiated involving many other types of costimulatory molecules
and cytokines. When immature DC were applied as the second
round, they were unable to revert the T cell activation program
back into an anergic state.
Figure 3. A single allogeneic T cell priming by lowGM-DC does
not induce T cell anergy. Allogeneic T cells were stimulated with
either immature lowGM-DC or immature highGM+IL-4-DC or LPS-
matured highGM+IL-4-DC. After 5 days the T cells were restimulated
with IL-2 or the indicated antibodies or LPS-matured DC from the
original allotype (matDC allo) or a third party allotype (matDC 3rd) or
cells were left without stimulation (control) for another 3 days before
[3H]-thymidine ([3H]-Th.) was added overnight to measure proliferation
as shown in the flow chart. The data from one experiment shown are
representative of 5 independent experiments. Values represent the
mean6standard deviation error bars of triplicate cultures from one
experiment.
doi:10.1371/journal.pone.0006645.g003
Maturation-Resistant DC
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In conclusion, we provide a protocol that allows the generation of
immature and maturation-resistant DC according to GMP
guidelines to induce allogeneic transplantation tolerance. Further-
more, by using DC for anergy induction, which represent more
physiological conditions as compared with antibody studies, our data
allow us to speculate how immature DC could induce T cell anergy
by two subsequent stimulations involving CTLA-4 signalling.
Materials and Methods
Ethics Statement
BM samples were received from patients with various
hematological disorders who were in clinical remission following
appropriate therapy and who were seen for routine follow-up that
included BM analysis. Informed written consent of all the patients
to this study was obtained before BM sample acquisition. BM
sampling and the experimental work occurred after approval from
the Ethical Committee of the Medical Faculty at the University of
Erlangen (approval no. 2856).
Generation of human BM-DC
Heparinized BM samples were diluted 1:4 in PBS and layered
on a density gradient (LymphoprepH, Nycomed Pharma AS) and
centrifuged (4866g/30 min/20uC). Interphase cells were collected
and plated at a density of 56106 cells/10 cm petri dish (Falcon
#1029) in 10 ml R10 medium consisting of RPMI 1640 (Bio-
Whittaker (Cambrex, Vervier, Belgium) with heat inactivated 1%
AB plasma (kindly provided from the Department of Transfusion
Medicine, University of Erlangen), 100 U/ml penicillin, 100 mg/
ml streptomycin (PAA) and L-Glutamin (PAA). Generation of
human BM-DC followed then largely the protocol established for
murine lowGM cultures, described before [23]. Briefly, 4–5.56106
BM cells per 10 cm petri dish (Falcon, #3003) were seeded and
cultured under highGM conditions received 800 U/ml rhGM-
CSF plus 250 U/ml rhIL-4 (both Cell Genix, Freiburg, Germany).
LowGM conditions contained 5 U/ml rhGM-CSF. At each days
4 and 6 additional 3 ml R10 were added containing the the same
low or high doeses of GM-CSF6IL-4. Cells were used for
functional assays at day 7. For DC maturation LPS (100 ng/ml,
Figure 4. Allogeneic T cell anergy induction requires two stimulations by lowGM-DC. A. Allogeneic T cells were stimulated twice (for 5
days and then for another 3 days) with either immature lowGM-DC or immature highGM+IL-4-DC or mature highGM+IL-4-DC and then restimulated a
third time for another 3 days with IL-2 or the indicated antibodies or LPS-matured DC from the original allotype (matDC allo) or a third party allotype
(matDC 3rd) or cells were left without stimulation (control) for another 3 days. B. Then [3H]-thymidine ([3H]-Th.) was added overnight to measure
proliferation. The data are representative of 4 independent experiments. C. Supernatants from the cultures shown in Figure 4B were tested for their
content of IL-2, IFN-c, or IL-10 by cytokine bead array (CBA). The relative mean fluorescence values of the FACS analysis are shown. The data from one
experiment shown are representative for 3 independent experiments. Values in bar graphs represent the mean6standard deviation error bars of
triplicate cultures from one experiment. D. CFSE-labeled T cells were restimulated by the indicated DC type for 4 days and then stained for
intracellular expression of Foxp3. Cells were measured by flow cytometry. Gating was performed on CFSE+ cells and is plotted against Foxp3 or
isotype. CFSElow cells represent allo-responsive proliferated cells.
doi:10.1371/journal.pone.0006645.g004
Maturation-Resistant DC
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SIGMA), Poly I:C (50 mg/ml, Pharmacia), CD40L (300 ng/ml) or
maturation cocktail, consisting of 10 ng/ml TNF, 13.2 ng/ml IL-
1b, 1000 U/ml IL-6, 1 mg/ml PGE2 (Cell Genix, Freiburg,
Germany) was added over night.
The DC that were used in this study were generated from BM
cells of routine follow-up patients with various hematological
disorders. The cellular yields and the functional quality of the DC
was comparable in all the experiments that were performed,
indicating that no disease-specific factors had influenced the BM
quality and thereby modulate DC function. Similar data regarding
the maturation-resistant DC phenotype by using the protocol for
lowGM-DC generation were also obtained from cord blood
CD34+ cells. These findings further support that the diseases did
influence the LowGM-DC generation.
Mature DC and T cell sources
As a control for the less established BM-DC cultures, Mo-DC
were generated as stimulators in the allogeneic T cell assays. For
allogeneic T cell stimulation the non-adherent fraction (NAF) of
cells from peripheral blood mononuclear cells (PBMC) from
healthy donors were used. Peripheral blood samples were treated
as the BM cells above to obtain PBMC in the interphase. These
cells were then plated at a density of 26106 per 10 cm petri dish
(Falcon #3003) for 1–2 h to obtain adherent monocytes cells for
DC generation and the NAF which was used as a source of T cells.
The well standardized Mo-DC culture was performed as described
in detail before [50].
Flow cytometry
DC or T cells were harvested and stained for 30 min on ice,
each step with the following antibodies: HLA-DR, CD40, CD83,
CD86, all conjugated with FITC and CD3-PE (Becton Dickinson).
In the experiments where Foxp3 was determined, cells were
labelled with carboxyfluorescein-succinimidylester (CFSE, Molec-
ular Probes, 5 mM, 15 min at room temparature) before the
stimulation by DC and stained intracellularly with Foxp3-APC
conjugate after 4 days of culture according to the manufacturer’s
descriptions (e-bioscience). Samples were analysed using a
FACScan or FACS Canto II (Becton Dickinson). To measure
cytokine production the supernatants of the T cell cultures were
visualized by cytokine bead array (CBA by BD) according to the
manufacturer’s recommendations and analysed by a FACScan.
Allogeneic T cell stimulation
As a T cell source the NAF was used and the cells were cultured
for primary stimulations in 24-well plates at 16106 cells/well
together with the indicated maturation stage of allogeneic DC at
16105/well for 5 days. Aliquots of the respective maturation stage
of DC from this donor were stored frozen for subsequent
restimulations with the same DC allotype and maturation stage.
T cell restimulation by DC occurred by adding 16105 DC/well.
After one or two round of stimulation by DC another the T cell
cultures were restimulated as triplicate cultures in flat bottom 96-
well plates at 36105 T cells/well (i.e. NAF) and 36104 DC/well
(initial allotype or third party, as indicated) or with 1000 U/ml
rhIL-2 or precoated anti-CD3 alone or precoated anti-CD3 plus
soluble anti-CD28 (both 10 mg/ml, Becton Dickinson). After 3
days [3H]-thymidine (Amersham) was added overnight and
proliferation measured with a 96-well harvester (TOMTEC) and
the filters counted in a 1450 Microbeta Counter Wallac-Trilux.
Results were acquired with a Microbeta Windows Workstation
program and analyzed in Excel.
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